Source: International Congress 2016 – IPF treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mark Fisher (St Albans, United Kingdom), Mark Fisher, Toby M. Maher, Steven D. Nathan, Christian Hill, Jade Marshall, Fred Dejonckheere, Per-Olof Thuresson, Nitya Mathew. Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF). Eur Respir J 2016; 48: Suppl. 60, 4964

Member's Comments

No comment yet.

Related content which might interest you: A longitudinal study of anxiety and depression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us? Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 The efficacy of a walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis (IPF). A pilot study Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Pulmonary rehabilitation (PR) exercise tolerance improvement: Differences between interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study Source: Annual Congress 2006 - Quality of life in various respiratory diseases Year: 2006 The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry Source: International Congress 2016 – IPF clinical Year: 2016 The physical and psychological needs of patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Palliative and end-of-life care for patients with respiratory disease Source: Eur Respir Mon; 2009: 43:327–353 Year: 2009 The lived experience of idiopatic pulmonary fibrosis: A qualitative study Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016 Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Real life patient experience of pirfenidone in a regional interstitial lung disease clinic Source: International Congress 2015 – IPF: from bench to bedside Year: 2015